BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
4418308
Number of visits today
1939
Number of downloads
4053725
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Fontes-sousa M, Calvo E. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Rini BI, Brugarolas J, Atkins MB. Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma. J Immunother Cancer 2023;11. [PMID: 36898737 DOI: 10.1136/jitc-2022-006361] [Reference Citation Analysis]
2 Climent C, Soriano S, Bonfill T, Lopez N, Rodriguez M, Sierra M, Andreu P, Fragio M, Busquets M, Carrasco A, Cano O, Seguí MA, Gallardo E. The role of immunotherapy in non-clear cell renal cell carcinoma. Front Oncol 2023;13:941835. [PMID: 36816976 DOI: 10.3389/fonc.2023.941835] [Reference Citation Analysis]
3 Monteiro FSM, Soares A, Rizzo A, Santoni M, Mollica V, Grande E, Massari F. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis. Clin Genitourin Cancer 2023:S1558-7673(23)00025-3. [PMID: 36823017 DOI: 10.1016/j.clgc.2023.01.005] [Reference Citation Analysis]
4 Zhu S, Yu C, Wang C, Ding G, Cheng S. Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation. Front Oncol 2022;12:969106. [DOI: 10.3389/fonc.2022.969106] [Reference Citation Analysis]
5 Basso U, Paolieri F, Rizzo M, De Giorgi U, Bracarda S, Antonuzzo L, Atzori F, Cartenì G, Procopio G, Fratino L, D'Arcangelo M, Fornarini G, Zucali P, Cusmai A, Santoni M, Pipitone S, Carella C, Panni S, Deppieri FM, Zagonel V, Tortora G. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers (Basel) 2022;14. [PMID: 35565422 DOI: 10.3390/cancers14092293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345